STOCK TITAN
  1. Home
  2. News
  3. RNAC

Cartesian - RNAC STOCK NEWS

Welcome to our dedicated page for Cartesian news (Ticker: RNAC), a resource for investors and traders seeking the latest updates and insights on Cartesian stock.

Cartesian Therapeutics, Inc. (symbol: RNAC) is a clinical-stage biopharmaceutical company dedicated to developing innovative RNA-based therapies. The company utilizes its proprietary RNA Armory® platform, which introduces mRNA molecules into cells to enhance their function while naturally degrading over time without integrating into the cell's genetic material. This technology aims to provide precise control and optimization of engineered cells for a variety of cell therapies.

Cartesian Therapeutics is currently focusing on several key projects, including Descartes-08 for treating myasthenia gravis and Descartes-15, which targets systemic lupus erythematosus. These promising therapies are part of the company's portfolio of candidates that leverage multiple modalities to address complex diseases. The company's leading candidate, Descartes-08, is in its Phase 2b trial, with topline data expected by mid-2024.

The company has formed strategic partnerships to further enhance its research and development efforts. These collaborations aim to expedite the clinical trials and bring novel treatments to market efficiently. Cartesian Therapeutics also maintains a strong financial position, ensuring sufficient resources to advance its pipeline projects.

Investors and stakeholders can stay informed about the company's latest developments through regular updates on financial performance, clinical trial progress, and strategic initiatives. Recent news highlights include the approval of proposals at the company's special meeting of stockholders held on March 27, 2024, and the ongoing positive trajectory of clinical trials.

In summary, Cartesian Therapeutics is at the forefront of biopharmaceutical innovation, utilizing cutting-edge RNA technology to develop therapies for unmet medical needs. The company's commitment to advancing its pipeline and maintaining strategic partnerships positions it as a significant player in the biopharmaceutical industry.

News

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) to present at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024, discussing mRNA cell therapy for autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences
-
News

Cartesian Therapeutics Announces New Employment Inducement Grants

Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) grants inducement awards to four new employees, offering them options to purchase shares of the company's common stock. The options amount to 765,000 shares with an exercise price of $0.5601 per share, vesting over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
-
News

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Rhea-AI Summary
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) announced stockholder approval for the conversion of Series A Non-Voting Convertible Preferred Stock into common stock and a 1-for-30 reverse stock split. The reverse stock split will reduce outstanding shares from 165.5 million to 5.5 million, maintaining trading under the symbol 'RNAC'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.85%
Tags
stock split
News

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) reports positive Phase 2b study data for Descartes-08 mRNA CAR-T therapy in myasthenia gravis (MG). The Company plans to initiate Phase 2 studies in systemic lupus erythematosus (SLE) and other autoimmune indications. Recent IND clearance for Descartes-15 for multiple myeloma. Financially, the company holds approximately $118.3M in cash, supporting operations until the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
earnings
-
News

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) to present at two investor conferences in March 2024, showcasing mRNA cell therapy for autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
conferences
-
News

Cartesian Therapeutics Announces New Employment Inducement Grant

Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) granted an inducement award to a new employee, offering 375,000 shares at $0.69 per share. The option vests over four years, fully by 2028, under Nasdaq Listing Rules. The award aims to attract and retain talent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
News

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) plans to transition its corporate headquarters to Frederick, Maryland, to support expanded cGMP manufacturing of mRNA cell therapies for autoimmune diseases. The new 20,000 square foot facility will enable the company to scale its manufacturing capabilities for late-stage clinical and commercial supply while maintaining product quality.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
-
News

Cartesian Therapeutics Announces New Employment Inducement Grants

Rhea-AI Summary
Cartesian Therapeutics, Inc. announced the granting of inducement awards to five new employees, issuing them options to purchase shares of the company's common stock. The options have a per share exercise price of $0.75 and are exercisable for an aggregate of 708,546 shares. Each option vests over time and has a ten-year term. The options were granted under Nasdaq Listing Rules as inducements material to each employee's entry into employment with the Company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
none
-
News

Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

Rhea-AI Summary
Cartesian Therapeutics, a clinical-stage biotechnology company (NASDAQ: RNAC), highlighted its recent progress and outlined 2024 strategic priorities across its pipeline of mRNA cell therapy product candidates. The company reported positive 12-month follow-up data from Phase 2a study of Descartes-08 in myasthenia gravis, with durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores. The company also announced the expansion of its clinical pipeline following recent IND clearance for Descartes-15, a next-generation mRNA CAR-T product candidate. Cartesian ended 2023 with approximately $118M pro forma cash and cash equivalents, expected to support planned operations into the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
none
News

Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

Rhea-AI Summary
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) announced positive twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis (MG), a chronic autoimmune disorder. Descartes-08, an autologous anti-B-cell maturation antigen (BCMA) mRNA CAR-T, showed durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores without the need for lymphodepleting chemotherapy. The manuscript titled, 'Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell Therapy,' has been submitted for peer-review and can be accessed on the online preprint server, medRxiv. Topline data from a Phase 2b placebo-controlled study is expected in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
clinical trial

FAQ

What is the current stock price of Cartesian (RNAC)?

The current stock price of Cartesian (RNAC) is $18.84 as of February 28, 2025.

What is the market cap of Cartesian (RNAC)?

The market cap of Cartesian (RNAC) is approximately 463.3M.

What does Cartesian Therapeutics, Inc. do?

Cartesian Therapeutics is a clinical-stage biopharmaceutical company that develops RNA-based therapies to enhance cell function and treat complex diseases.

What is the RNA Armory® platform?

The RNA Armory® platform introduces mRNA molecules into cells, enhancing their function without integrating into the cell's genetic material.

What are Cartesian Therapeutics' key projects?

Key projects include Descartes-08 for myasthenia gravis and Descartes-15 targeting systemic lupus erythematosus.

What is the status of Descartes-08?

Descartes-08 is in its Phase 2b trial, with topline data expected by mid-2024.

How does Cartesian Therapeutics ensure the success of its clinical trials?

The company forms strategic partnerships to expedite clinical trials and efficiently bring novel treatments to market.

What recent achievements has Cartesian Therapeutics announced?

Recent achievements include the approval of proposals at the special meeting of stockholders on March 27, 2024, and progress in clinical trials.

What makes Cartesian Therapeutics unique in the biopharmaceutical industry?

The company uses cutting-edge RNA technology to develop therapies that precisely control and optimize engineered cells.

How does Cartesian Therapeutics support its financial health?

The company maintains a strong financial position, ensuring sufficient resources to advance its pipeline projects.

Where can investors find updates about Cartesian Therapeutics?

Investors can find updates on the company's financial performance, clinical trial progress, and strategic initiatives through regular news releases.

What is the significance of Cartesian Therapeutics' RNA therapies?

The company's RNA therapies aim to address unmet medical needs with precision and optimization, positioning it as a leader in biopharmaceutical innovation.
Stock RNAC logo
Cartesian

Nasdaq:RNAC

RNAC Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

RNAC Stock Data

463.31M
10.26M
60.4%
28.06%
7.81%
Biotechnology
Pharmaceutical Preparations
Link
United States
FREDERICK